Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline
Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline
Bristol Myers Squibb will be responsible for developing, manufacturing, and commercializing next-generation cell therapies, with support from Prime Medicine in gene editing strategy and reagent development.On Monday, Prime Medicine Inc. (NASDAQ:PRME) announced a strategic research collaboration and license agreement with Bristol Myers Squibb & Co (NYSE:BMY) to develop reagents for the next generation of ex vivo T-cell therapies.
本周一，Prime Medicine Inc.（纳斯达克:PRME）宣布与Bristol Myers Squibb＆Co（纽交所:BMY）达成战略研究合作和许可协议，共同开发用于下一代离体t细胞疗法的试剂。
Under the terms of the agreement, Prime Medicine will design optimized Prime Editor reagents for a select number of targets, including reagents that use its Prime Assisted Site-Specific Integrase Gene Editing (PASSIGE) technology.
根据协议条款，Prime Medicine将设计优化的Prime Editor试剂，针对若干目标，包括使用其Prime Assisted Site-Specific Integrase Gene Editing（PASSIGE）技术的试剂。
Also Read: Preclinical-Phase Firm Prime Medicine's Gene Editing Platform Has Potential: Analyst.
分析师称：临床前阶段公司Prime Medicine的基因编辑平台具有潜力。
Bristol Myers Squibb will be responsible for developing, manufacturing, and commercializing next-generation cell therapies, with support from Prime Medicine in gene editing strategy and reagent development.
Bristol Myers Squibb将负责开发、制造和商业化下一代细胞疗法，Prime Medicine将在基因编辑策略和试剂开发方面提供支持。
Prime Medicine will receive a $55 million upfront payment and a $55 million equity investment from Bristol Myers Squibb.
Prime Medicine将获得Bristol Myers Squibb提前付款5500万美元和5500万美元的股权投资。
Prime Medicine is also eligible to receive more than $3.5 billion in milestones, including up to $1.4 billion in development milestones and more than $2.1 billion in commercialization milestones, along with royalties on net sales.
Prime Medicine还有权获得超过35亿美元的里程碑奖励，包括高达14亿美元的开发里程碑和超过21亿美元的商业化里程碑，以及净销售额提成。
Concurrently, Prime Medicine announced that it would streamline its pipeline.
与此同时，Prime Medicine宣布将简化其产品线。
The company said it will focus on developing two programs for chronic granulomatous disease (CGD).
该公司表示将专注于为慢性肉芽肿病（CGD）开发两个项目。
- PM359, an ex vivo autologous hematopoietic stem cell (HSC) product: The company has initiated a Phase 1/2 clinical trial to assess the safety, biological activity, and preliminary efficacy of PM359 in adult and pediatric patients and expects initial clinical data study in 2025.
- Ex vivo HSC product for the treatment of X-linked CGD
- PM359是一种体外自体造血干细胞（HSC）产品：该公司已经启动了一项阶段1/2临床试验，以评估PM359在成人和儿童患者中的安全性、生物活性和初步疗效，并预计在2025年进行初步临床数据研究。
- 用于治疗X连锁遗传性过氧化物酶缺乏症的体外HSC产品
Other candidates that the company will prioritize include:
该公司将优先考虑的其他候选者包括：
- Lipid nanoparticle (LNP) Prime Editor for Wilson's Disease: Prime Medicine expects to present new preclinical data and initiate IND-enabling activities in the fourth quarter of 2024 and intends to file an IND and/or clinical trial application in the first half of 2026.
- LNP / adeno-associated virus Prime Editors for the treatment of Cystic Fibrosis.
- 用于威尔逊氏病的脂质纳米粒（LNP）Prime Editor：Prime Medicine预计将于2024年第四季度展示新的临床前数据，并启动IND启动活动，并计划在2026年上半年提交IND和/或临床试验申请。
- 用于治疗囊性纤维化的脂质纳米粒（LNP）/腺相关病毒Prime Editor。
With the $110 million upfront consideration received from Bristol Myers Squibb under the strategic research collaboration and license agreement announced this morning, Prime Medicine expects its cash runway to fund operations into the first half of 2026.
通过宣布今天早晨与百时美施贵宝达成的战略研究合作和许可协议获得的1.1亿美元的预付款，Prime Medicine预计其现金运营能力将支持至2026年上半年。
Prime Medicine is identifying partnership opportunities to advance its other programs, including those for neurological diseases, cell therapy, ocular diseases, and hearing loss.
Prime Medicine正在寻找合作机会，推进其其他项目，包括神经疾病、细胞治疗、眼科疾病和听力丧失项目。
Price Action: PRME stock is up 17.1% at $4.05 during the premarket session at last check Monday.
价格走势：PRME股票在周一的盘前交易时上涨了17.1%，报价4.05美元。
Photo via Shutterstock
图片来自shutterstock。
- What's Going On With Alibaba Stock On Monday?
- 阿里巴巴股票星期一发生了什么？
